Reference priceRUB ₽15,840.00Original source price: INR 14,400.00. Converted estimates are available by currency selection.
| Brand | Mvasi |
|---|---|
| Manufacturer | Amgen Inc. |
| Prescription required | Yes |
Mvasi injection 100mg/4ml(bevacizumab-awwb)
bevacizumab-awwb
Description
Mvasi injection 100mg/4ml(bevacizumab-awwb) is a medicine catalog record in the MediPriceHub database. Active ingredient: bevacizumab-awwb. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Amgen Inc.. Therapeutic category: Medicine Library > Oncology Medicines > Colorectal Cancer Medicines. Pack information: 100 / 4 (25 / ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. Recurrent glioblastoma in adults. Metastatic renal cell carcinoma in combination with interferon-alfa. Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection in combination with paclitaxel, pegylated liposomal doxorubicin, or tHow to Use
Use bevacizumab-awwb under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: bevacizumab-awwb. Pack size: 100 / 4 (25 / ). Pack unit: bottle. Manufacturer: Amgen Inc.. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Colorectal Cancer Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.Эта информация носит справочный характер. Перед применением лекарства проконсультируйтесь с медицинским специалистом.